Comparison of oral folic acid and folinic acid on blood homocysteine level of patients on hemodialysis

Iranian Journal of Kidney Diseases

Volumn 5, Issue 1, 2011, Pages 45-49

  Soleimani, Alireza ^a   Usefzadeh, Mojtaba ^a   Mianehsaz, Elahe ^a   Foroozanfard, Fatemeh ^a   Nikoueinejad, Hassan ^a   Moraveji, Seyyed Alireza ^a   Nasiri, Omid ^a   Rajali, Mohsen ^a  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Folic acid; Hemodialysis; Hyperhomocysteinemia

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; VITAMIN B COMPLEX; VITAMIN B GROUP;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; RENAL DIALYSIS; STATISTICS, NONPARAMETRIC;

EID: 79251479407     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mahdavi M, Anoushirvani AA, Abol Ghasemi R, Kalantar E. A randomized study of folic acid therapy with less than 5 mg/day and 7.5 mg/day in hyperhomocysteinemic hemodialysis patients. J Mazandaran Univ Med Sci. 2006;50:41-8. Persian.
2. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol. 2001;12:2181-9.
3. Horl WH, Cohen JJ, Harrington JT, Madias NE, Zusman CJ. Atherosclerosis and uremic retention solutes. Kidney Int. 2004;66:1719-31.
4. Tiwari SC, Raju SB. Homocysteine in renal disease. Indian Acad Clin Med J. 2000;1:149-530.
5. Perna AF, De Santo NG, Ingrosso D. Adverse effects of hyperhomocysteinemia and their management by folic acid. Miner Electrolyte Metab. 1997;23:174-8.
6. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554-8.
7. Stam F, van Guldener C, Ter Wee PM, Jakobs C, de Meer K, Stehouwer CD. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int. 2005;67:259-64.
8. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138-41.
9. Bayes B, Pastor MC, Bonal J, Junca J, Romero R. Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E. Nephrol Dial Tran plant. 2001;16:2172-5.
10. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-92.
11. Righetti M, Ferrario GM, Milani S, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit. 2003;9:PI19-24.
12. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol. 1997;8:1899-905.
13. Bostom AG, Gohh RY, Beaulieu AJ, et al. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med. 1997;127:1089-92.
14. Jungers P, Joly D, Massy Z, et al. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant. 1999;14:2903-6.
15. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drueke T, Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. 1999;56:2292-6.
16. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Lond). 1999;96:235-9.
17. Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995;25:176-81.
18. Anderson TJ, Sun YH, Hubacek J, et al. Effects of folinic acid on forearm blood flow in patients with end-stage renal disease. Nephrol Dial Transplant. 2006;21:1927-33.
19. Ducloux D, Aboubakr A, Motte G, et al. Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant. 2002;17:865-70.
20. Bostom AG, Shemin D, Gohh RY, et al. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int Suppl. 2001;78:S246-52.
21. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl. 1996;57:S11-7.
22. Yango A, Shemin D, Hsu N, et al. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int. 2001;59:324-7.
23. Apeland T, Mansoor MA, Seljeflot I, Bronstad I, Goransson L, Strandjord RE. Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. J Intern Med. 2002;252:456-64.
24. Hauser AC, Hagen W, Rehak PH, et al. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. Am J Kidney Dis. 2001;37:758-65.
25. Armada E, Perez C, Otero A, et al. Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients. Clin Nephrol. 2003;60:168-75.
26. Gonin JM, Nguyen H, Gonin R, et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol. 2003;16: 522-34.
27. Anderson TJ, Sun YH, Hubacek J, et al. Effects of folinic acid on forearm blood flow in patients with end-stage renal disease. Nephrol Dial Transplant. 2006;21:1927-33.
28. Shojaei MH, Djalali M, Siassi F, Khatami MR, Boroumand MA, Eshragian MR. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid. Iran J Kidney Dis. 2009;3:141-4.
29. Heinz J, Domrose U, Westphal S, Luley C, Neumann KH, Dierkes J. Washout of water-soluble vitamins and of homocysteine during haemodialysis: effect of high-flux and low-flux dialyser membranes. Nephrology (Carlton). 2008;13:384-9.
30. Ossareh S, Shayan-Moghaddam H, Salimi A, Asgari M, Farrokhi F. Different doses of oral folic acid for homocysteine-lowering therapy in patients on hemodialysis: a randomized controlled trial. Iran J Kidney Dis. 2009;3:227-33.
31. Dierkes J, Luley C, Westphal S. Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag. 2007;3:99-108.
32. Alvares Delfino VD, de Andrade Vianna AC, Mocelin AJ, Barbosa DS, Mise RA, Matsuo T. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients. Nutrition. 2007;23:242-7.
33. Chang TY, Chou KJ, Tseng CF, et al. Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients. Curr Med Res Opin. 2007;23:1879-86.
34. Azadibakhsh N, Hosseini RS, Atabak S, Nateghiyan N, Golestan B, Rad AH. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients. Saudi J Kidney Dis Transpl. 2009;20:779-88.